Cosmo Pharma Rises on Bowel Disease Drug Approval: Zurich Mover

Published January 15, 2013

Cosmo Pharma Rises on Bowel Disease Drug Approval: Zurich Mover

Filed under: outpatient drug treatment programs

Cosmo Pharmaceuticals SpA (COPN), an Italian developer of a drug for a type of bowel disease, rose to a record after its U.S. partner Santarus Inc. (SNTS) won regulatory approval for the treatment. Cosmo climbed as much as 10 percent to 38 Swiss francs …
Read more on Bloomberg

Analysis: Drug industry bets on new blockbusters in 2013

Filed under: outpatient drug treatment programs

Doctors treating diabetes are also likely to have new drugs before the year is out, with a new class of medicines that work via the kidneys seen entering the fray. The SGLT2 inhibitors for type 2 diabetes had a setback when dapagliflozin from …
Read more on Reuters

Swindon shows the way in drugs fight

Filed under: outpatient drug treatment programs

Insp Paul Saunders, Partnership Inspector for Swindon, said: “The recent experiences in Swindon have led to education initiatives for drug users through the drug treatment services, training for front-line staff in both police and council roles on the …
Read more on Swindon Advertiser